↓ Skip to main content

Therapeutic landscape in mutational triple negative breast cancer

Overview of attention for article published in Molecular Cancer, July 2018
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)

Mentioned by

9 tweeters


33 Dimensions

Readers on

83 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Therapeutic landscape in mutational triple negative breast cancer
Published in
Molecular Cancer, July 2018
DOI 10.1186/s12943-018-0850-9
Pubmed ID

Yaqin Shi, Juan Jin, Wenfei Ji, Xiaoxiang Guan


Triple negative breast cancer (TNBC) is a heterogeneous disease with aggressive behavior and poor prognosis. Genomic sequencing has detected a distinctive mutational portrait of both the germline and somatic alterations in TNBC, which is staggeringly different from other breast cancer subtypes. The clinical utility of sequencing germline BRCA1/2 genes has been well established in TNBC. However, for other predisposition genes, studies concerning the risk and penetrance to TNBC are relatively scarce. Very few recurrent mutations, including TP53 and PI3KCA mutations, together with a long tail of individually rare mutations occur in TNBC. These combined effects of genomic alterations drive TNBC progression. Given the complexity and heterogeneity of TNBC, clinical interpretation of the genomic alterations in TNBC may pave a new way for the treatment of TNBC. In this review, we summarized the germline and somatic mutation profiles of TNBC and discussed the current and upcoming therapeutic strategies targeting the mutant proteins or pathways to enable tailored-therapeutics.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 83 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 16 19%
Student > Bachelor 13 16%
Researcher 13 16%
Student > Master 9 11%
Student > Doctoral Student 4 5%
Other 13 16%
Unknown 15 18%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 22 27%
Medicine and Dentistry 17 20%
Agricultural and Biological Sciences 9 11%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Immunology and Microbiology 4 5%
Other 9 11%
Unknown 18 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 April 2020.
All research outputs
of 17,946,015 outputs
Outputs from Molecular Cancer
of 1,408 outputs
Outputs of similar age
of 286,856 outputs
Outputs of similar age from Molecular Cancer
of 1 outputs
Altmetric has tracked 17,946,015 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 1,408 research outputs from this source. They receive a mean Attention Score of 4.0. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,856 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them